Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Equity (2016 - 2025)

Historic Return on Equity for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 0.15%.

  • Neurocrine Biosciences' Return on Equity rose 200.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.15%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.16% for FY2025, which is 200.0% up from last year.
  • Neurocrine Biosciences' Return on Equity amounted to 0.15% in Q4 2025, which was up 200.0% from 0.15% recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Return on Equity ranged from a high of 0.16% in Q1 2024 and a low of 0.01% during Q1 2023
  • Moreover, its 4-year median value for Return on Equity was 0.12% (2025), whereas its average is 0.1%.
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by -2500bps in 2021, then surged by 1500bps in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Return on Equity stood at 0.07% in 2021, then skyrocketed by 60bps to 0.12% in 2023, then increased by 9bps to 0.13% in 2024, then increased by 19bps to 0.15% in 2025.
  • Its last three reported values are 0.15% in Q4 2025, 0.15% for Q3 2025, and 0.13% during Q2 2025.